Kikuchi Kazufumi, Togao Osamu, Kikuchi Yoshitomo, Yamashita Koji, Momosaka Daichi, Fukasawa Kazunori, Nishimura Shunsuke, Toyoda Hiroyuki, Obara Makoto, Hiwatashi Akio, Ishigami Kousei
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Department of Molecular Imaging & Diagnosis, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Neuroradiology. 2025 Feb;67(2):351-359. doi: 10.1007/s00234-024-03454-4. Epub 2024 Aug 22.
To verify the effectiveness of artificial intelligence-assisted volume isotropic simultaneous interleaved bright-/black-blood examination (AI-VISIBLE) for detecting brain metastases.
This retrospective study was approved by our institutional review board and the requirement for written informed consent was waived. Forty patients were included: 20 patients with and without brain metastases each. Seven independent observers (three radiology residents and four neuroradiologists) participated in two reading sessions: in the first, brain metastases were detected using VISIBLE only; in the second, the results of the first session were comprehensively evaluated by adding AI-VISIBLE information. Sensitivity, diagnostic performance, and false positives/case were evaluated. Diagnostic performance was assessed using a figure-of-merit (FOM). Sensitivity and false positives/case were evaluated using McNemar and paired t-tests, respectively.
The McNemar test revealed a significant difference between VISIBLE with/without AI information (P < 0.0001). Significantly higher sensitivity (94.9 ± 1.7% vs. 88.3 ± 5.1%, P = 0.0028) and FOM (0.983 ± 0.009 vs. 0.972 ± 0.013, P = 0.0063) were achieved using VISIBLE with AI information vs. without. No significant difference was observed in false positives/case with and without AI information (0.23 ± 0.19 vs. 0.18 ± 0.15, P = 0.250). AI-assisted results of radiology residents became comparable to results of neuroradiologists (sensitivity, FOM: 85.9 ± 3.4% vs. 90.0 ± 5.9%, 0.969 ± 0.016 vs. 0.974 ± 0.012 without AI information; 94.8 ± 1.3% vs. 95.0 ± 2.1%, 0.977 ± 0.010 vs. 0.988 ± 0.005 with AI information, respectively).
AI-VISIBLE improved the sensitivity and performance for diagnosing brain metastases.
验证人工智能辅助容积各向同性同步交错亮血/黑血检查（AI-VISIBLE）在检测脑转移瘤方面的有效性。
本回顾性研究经机构审查委员会批准，无需书面知情同意。纳入40例患者：每组20例有或无脑转移瘤的患者。七名独立观察者（三名放射科住院医师和四名神经放射科医生）参与了两次读片：第一次仅使用VISIBLE检测脑转移瘤；第二次通过添加AI-VISIBLE信息对第一次的结果进行综合评估。评估敏感性、诊断性能和假阳性/病例数。使用品质因数（FOM）评估诊断性能。分别使用McNemar检验和配对t检验评估敏感性和假阳性/病例数。
McNemar检验显示有无AI信息的VISIBLE之间存在显著差异（P < 0.0001）。与不使用AI信息的VISIBLE相比，使用AI信息的VISIBLE具有显著更高的敏感性（94.9±1.7%对88.3±5.1%，P = 0.0028）和FOM（0.983±0.009对0.972±0.013，P = 0.0063）。有无AI信息的假阳性/病例数无显著差异（0.
